The Oncology Institute, Inc.

Total Valuation

The Oncology Institute, Inc. carries a market capitalization of 5.42M, placing it among publicly traded companies globally. Its enterprise value stands at 74.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

The Oncology Institute, Inc. currently has 99.97M shares outstanding.

Enterprise Valuation

Financial Position

The Oncology Institute, Inc. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -643.89, indicating conservative leverage, while an interest coverage ratio of -3.39 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

The Oncology Institute, Inc.'s stock has declined approximately -21.20344% over the past 52 weeks. The 50-day moving average sits at 0.05, while the 200-day moving average is 0.11.

Income Statement

EBITDA reached -25.91M, while operating income came in at -32.68M.

Balance Sheet

The Oncology Institute, Inc. holds 30.28M in cash and equivalents against 104.86M in total debt, resulting in a net debt position of 48.33M. Total book value stands at -273.90M, with working capital of 37.51M providing operational flexibility.

Cash Flow

The Oncology Institute, Inc. produced -21.81M in operating cash flow over the past twelve months.

Margins

The Oncology Institute, Inc. operates with a gross margin of 15.12, reflecting its pricing power and cost economics. The operating margin of -5.99 and net profit margin of -7.97 provide insight into operational efficiency.

Scores

The Oncology Institute, Inc. posts an Altman Z-Score of 0.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.